-
Patients with both DM and PaC could not be differentiated on the basis of tumor size or clinical stage.
-
A retrospective analysis of newly-diagnosed brain metastases in patients with breast cancer revealed that those with HER-2 positive disease had more favorable survival than those who were HER-2 negative. Compared to those with "triple negative" disease (median survival 4.0 months) those who had HER-2 positive disease survived 17.1 months.
-
In a series of 154 patients taken to surgery for isolated hepatic perfusion to treat unresectable liver metastases, the hepatic response rate was 50% and the median progression-free and overall survival was 7.4 and 24.8 months, respectively.
-
-
-
Even as the HIV health care community continues to make progress in improving patients' adherence to antiretroviral medication regimens, there remain some growing and stubborn obstacles to individual patients achieving the 95-plus percent adherence rate deemed optimal.
-
HIV/HCV coinfected patients who do not respond early on to interferon treatment will gain nothing from continued treatment, according to a study that looked at whether interferon treatment could slow liver disease progression among patients who were nonresponders to early interferon plus ribavirin treatment.1
-
The critical need to address mental health issues has been recognized globally and in the United States, however, significant deficiencies in access to mental health care remain for the general population and for people living with HIV/AIDS, the authors of this review article warn.
-
Although many HIV infections occur in older adults, national guidelines recommend screening only for persons age 13 to 64 years. However, researchers have found that expanding screening in people age 55 to 75 can be reasonably cost effective under the following circumstances:
-
For too long medication adherence has been studied and viewed from the narrow perspective of how many and how frequently patients take their antiretroviral medications, an expert says.
